Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Characterize the Safety and Efficacy of Tafamidis Once Daily in the Treatment of Transthyretin Amyloid Cardiomyopathy in Chinese Participants

NCT04814186 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04814186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04814186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Characterize the Safety and Efficacy of Tafamidis Once Daily in the Treatment of Transthyretin Amyloid Cardiomyopathy in Chinese Participants
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
July 22, 2021
Completion date
October 16, 2023
Enrollment
53 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloid cardiomyopathy